electroCore, Inc. (ECOR)
NASDAQ: ECOR · Real-Time Price · USD
5.03
+0.13 (2.65%)
Nov 28, 2025, 1:00 PM EST - Market closed
electroCore Revenue
electroCore had revenue of $8.69M in the quarter ending September 30, 2025, with 32.58% growth. This brings the company's revenue in the last twelve months to $29.84M, up 27.90% year-over-year. In the year 2024, electroCore had annual revenue of $25.18M with 57.09% growth.
Revenue (ttm)
$29.84M
Revenue Growth
+27.90%
P/S Ratio
1.41
Revenue / Employee
$408,699
Employees
73
Market Cap
40.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.18M | 9.15M | 57.09% |
| Dec 31, 2023 | 16.03M | 7.44M | 86.57% |
| Dec 31, 2022 | 8.59M | 3.14M | 57.62% |
| Dec 31, 2021 | 5.45M | 1.96M | 55.93% |
| Dec 31, 2020 | 3.50M | 1.11M | 46.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ECOR News
- 19 days ago - electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - GlobeNewsWire
- 23 days ago - electroCore, Inc. (ECOR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - electroCore Announces Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025 - GlobeNewsWire
- 2 months ago - electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms - GlobeNewsWire
- 2 months ago - electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium - GlobeNewsWire
- 2 months ago - electroCore's Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire's 2025 Sleep Awards - GlobeNewsWire